AbbVie’s $10B Rova-T play ends in one last failure — R&D team shuts it all down
AbbVie’s Rova-T has failed its last clinical trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.